Taroh Satoh

Summary

Affiliation: Kinki University
Country: Japan

Publications

  1. ncbi request reprint Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk
    Takeshi Yoshida
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Int J Cancer 122:1530-8. 2008
  2. doi request reprint Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors
    Taroh Satoh
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Clin Cancer Res 15:3872-80. 2009
  3. doi request reprint Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer
    Taroh Satoh
    Kinki University School of Medicine, Osaka, Japan
    Invest New Drugs 30:1511-8. 2012
  4. doi request reprint Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase
    Takafumi Okabe
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 7:599-606. 2008
  5. pmc Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, 589 8511, Japan
    Invest New Drugs 28:844-53. 2010
  6. ncbi request reprint Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer
    Tomohiro Ozaki
    Department of Medical Oncology, Kinki University School of Medicine, Nara Hospital, Otoda, Ikoma, Nara, Japan
    Anticancer Res 27:2657-65. 2007
  7. doi request reprint First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study
    Yasushi Tsuji
    Department of Medical Oncology, KKR Sapporo Medical Center Tonan Hospital, Hokkaido, Japan
    Cancer Sci 103:1502-7. 2012
  8. doi request reprint Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer
    Taroh Satoh
    Kinki University School of Medicine, Osaka, Japan
    Cancer Chemother Pharmacol 69:439-46. 2012
  9. ncbi request reprint Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification
    Takafumi Okabe
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Cancer Res 67:2046-53. 2007
  10. doi request reprint Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors
    Toshio Shimizu
    Department of Medical Oncology, Kinki University School of Medicine, Ohno Higashi, Osaka Sayama, Japan
    Cancer Chemother Pharmacol 65:243-50. 2010

Detail Information

Publications28

  1. ncbi request reprint Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk
    Takeshi Yoshida
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Int J Cancer 122:1530-8. 2008
    ....
  2. doi request reprint Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors
    Taroh Satoh
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Clin Cancer Res 15:3872-80. 2009
    ..The aim of this study was to determine the maximum tolerated dose (MTD) and to assess the safety, pharmacokinetics, and antitumor activity of YM155 in patients with advanced refractory solid tumors...
  3. doi request reprint Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer
    Taroh Satoh
    Kinki University School of Medicine, Osaka, Japan
    Invest New Drugs 30:1511-8. 2012
    ..Inhibition of vascular endothelial growth factor (VEGF) signaling is a clinically validated therapeutic strategy in patients with metastatic CRC. Cediranib is an oral, highly potent VEGF signaling inhibitor of all three VEGF receptors...
  4. doi request reprint Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase
    Takafumi Okabe
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 7:599-606. 2008
    ....
  5. pmc Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, 589 8511, Japan
    Invest New Drugs 28:844-53. 2010
    ..This phase I trial was conducted to evaluate drug safety and pharmacokinetics as well as tumor response of sorafenib in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)...
  6. ncbi request reprint Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer
    Tomohiro Ozaki
    Department of Medical Oncology, Kinki University School of Medicine, Nara Hospital, Otoda, Ikoma, Nara, Japan
    Anticancer Res 27:2657-65. 2007
    ..The primary objective of this study was to determine the maximum tolerated dose (MTD), the toxicity profile and the recommended dose (RD) for phase II of a combination of S-1 and weekly administration of docetaxel...
  7. doi request reprint First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study
    Yasushi Tsuji
    Department of Medical Oncology, KKR Sapporo Medical Center Tonan Hospital, Hokkaido, Japan
    Cancer Sci 103:1502-7. 2012
    ..8 month target, indicating that sunitinib did not add to the antitumor activity of FOLFIRI. This study was registered with www.ClinicalTrials.gov (NCT00668863)...
  8. doi request reprint Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer
    Taroh Satoh
    Kinki University School of Medicine, Osaka, Japan
    Cancer Chemother Pharmacol 69:439-46. 2012
    ....
  9. ncbi request reprint Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification
    Takafumi Okabe
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Cancer Res 67:2046-53. 2007
    ..These results reveal distinct biochemical properties of endogenous mutant forms of EGFR expressed in NSCLC cell lines and may have implications for treatment of this condition...
  10. doi request reprint Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors
    Toshio Shimizu
    Department of Medical Oncology, Kinki University School of Medicine, Ohno Higashi, Osaka Sayama, Japan
    Cancer Chemother Pharmacol 65:243-50. 2010
    ..We have performed a phase I study to determine the safety profile, pharmacokinetics, and antitumor activity of D-19575 in Japanese patients with advanced solid tumors..
  11. doi request reprint Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor
    Hidetoshi Hayashi
    Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka Sayama, Osaka, Japan
    Cancer Sci 104:98-104. 2013
    ..In conclusion, OTS11101 was well tolerated in patients up to 3.0 mg once weekly and our biomarker analysis suggested that this anti-angiogenesis vaccine is biologically active...
  12. doi request reprint S-1 for the treatment of gastrointestinal cancer
    Taroh Satoh
    Osaka University Graduate School of Medicine, Department of Frontier Science for Cancer and Chemotherapy, 2 2 Yamadaoka, Suita City, Osaka, 565 0871, Japan
    Expert Opin Pharmacother 13:1943-59. 2012
    ..S-1 , a fourth-generation oral fluoropyrimidine that combines tegafur and two biochemical modulators: gimeracil and oteracil potassium, is now attracting considerable interest...
  13. doi request reprint A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial
    Takayasu Kurata
    Department of Medical Oncology, Kinki University, School of Medicine, Osaka Sayama, Osaka, Japan
    J Thorac Oncol 4:644-8. 2009
    ..A phase I study on relapsed small cell lung cancer (SCLC) was conducted to establish the toxicity and maximum tolerated dose of carboplatin with topotecan, and to observe the antitumor activity...
  14. ncbi request reprint Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells
    Masato Ikeda
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
    Cancer Lett 248:292-8. 2007
    ..Furthermore, depletion of survivin resulted in G(2)-M arrest, suggesting that down-regulation of survivin by p53 contributes to the p53-dependent G(2)-M checkpoint triggered by DNA damage...
  15. doi request reprint Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors
    Isamu Okamoto
    Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan
    Cancer Sci 103:2135-8. 2012
    ..In conclusion, elpamotide is well tolerated and our biomarker analysis indicates that this anti-angiogenic vaccine is biologically active. Clinical trial registration no. UMIN000008336...
  16. ncbi request reprint Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses
    Kenji Tamura
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Cancer Chemother Pharmacol 60:285-93. 2007
    ....
  17. doi request reprint Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 9:2825-33. 2010
    ..In conclusion, the maximum tolerated dose of BIBF 1120 in the current study was determined to be 200 mg twice daily, and our biomarker analysis indicated that this angiokinase inhibitor is biologically active...
  18. doi request reprint Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer
    Taroh Satoh
    Department of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Osaka, Japan
    Cancer Chemother Pharmacol 69:949-55. 2012
    ..To evaluate the pharmacokinetics (PK) of capecitabine and cisplatin, administered in combination with or without trastuzumab, in Japanese patients with HER2-positive advanced gastric cancer (AGC)...
  19. ncbi request reprint Pemetrexed-induced edema of the eyelid
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi Osaka Sayama, Osaka 589 8511, Japan
    Lung Cancer 54:241-2. 2006
    ..We experienced a patient who developed the valuable edema of the eyelid. We believe that medical oncologists should be aware of this rare adverse event, although the mechanism responsible for it is not yet known...
  20. ncbi request reprint Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience
    Toshio Shimizu
    Department of Medical Oncology, Kinki University Nara Hospital, 1248 1 Otoda cho, Ikoma, Nara, 630 0293, Japan
    Int J Clin Oncol 12:218-23. 2007
    ..The oxaliplatin/fluorouracil/leucovorin (FOL-FOX regimen) is an effective and generally well-tolerated regimen in Western clinical studies of advanced colorectal cancer. In Japan, oxaliplatin was approved in April 2005...
  21. ncbi request reprint Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    J Thorac Oncol 1:684-91. 2006
    ....
  22. doi request reprint Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure
    Koichi Azuma
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohnohigashi, Osakasayama, Osaka 589 8511, Japan
    Biochem Biophys Res Commun 407:219-24. 2011
    ....
  23. doi request reprint Disturbance of the growth hormone-insulin-like growth factor-1 axis associated with poor performance status in patients with solid tumors
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Jpn J Clin Oncol 40:222-6. 2010
    ..However, little is known about changes in the GH-IGF-1 axis in cancer patients...
  24. doi request reprint A Phase I/II trial of radiotherapy concurrent with TS-1 plus cisplatin in patients with clinically resectable type 4 or large type 3 gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1205
    Motohiro Imano
    Department of Surgery, Kinki University Faculty of Medicine, Osaka Sayama, Osaka, Japan
    Jpn J Clin Oncol 43:431-5. 2013
    ..In Phase II, a total of 30 patients will be enrolled in the Osaka Gastrointestinal Cancer Chemotherapy Study Group trial over a period of 6 years...
  25. doi request reprint Reversible posterior leukoencephalopathy syndrome and trastuzumab
    Hiroyasu Kaneda
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Invest New Drugs 30:1766-7. 2012
    ..Given the increasing use of trastuzumab in patients with breast cancer, gastric cancer, or other solid tumors, physicians should be aware of this syndrome associated with acute hypertension during trastuzumab treatment...
  26. doi request reprint Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms
    Taroh Satoh
    Department of Medical Oncology, Kinki University Faculty of Medicine, Osakasayama, Japan
    Cancer Sci 102:1868-73. 2011
    ..UMIN Clinical Trial Registration number: UMIN000000618...
  27. ncbi request reprint Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)
    Shinzoh Kudoh
    Department of Respiratory Medicine, Osaka City University Medical School, Osaka, Japan
    J Clin Oncol 24:3657-63. 2006
    ..This randomized phase III trial evaluated the efficacy and safety of docetaxel versus vinorelbine (the current standard treatment) in elderly patients...
  28. ncbi request reprint Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin
    Kimio Yonesaka
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Int J Cancer 118:812-20. 2006
    ..siRNA targeting of survivin could be potentially useful for increasing sensitivity to anticancer drugs, especially in drug-resistant cells with mutated p53...